PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents growing 38.68% while GNPX's declined -61.17%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
Below half of GNPX's -50.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
101.21%
Higher PP&E (Net) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
Below half of GNPX's -4.04%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Below half of GNPX's -36.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-44.89%
1.1-1.25x GNPX's -38.99%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Similar yoy changes to GNPX's 144.34%. Walter Schloss finds parallel near-term liability trends.
112.59%
Above 1.5x GNPX's 13.75%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Above 1.5x GNPX's 13.75%. Michael Burry sees a potential leverage warning sign.
-89.62%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
-9.70%
≥ 1.5x GNPX's -2.94%. David Dodd sees higher yoy retained profits than competitor.
98.99%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
100.73%
Higher Other Stockholders' Equity Items Growth compared to GNPX's zero value, indicating worse performance.
-358.06%
≥ 1.5x GNPX's -64.03%. David Dodd sees stronger capital base growth than competitor.
42.36%
Below half GNPX's -36.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.